Cardiome pharma corp (CORV)
CashFlow / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Operating activities:
Net loss

-29,811

-19,619

-24,462

-18,227

4,773

-18,315

-27,920

35,499

Items not affecting cash:
Amortization (notes 8 and 9)

3,517

2,984

2,177

2,150

649

1,229

1,095

1,154

Accretion of long-term debt (note 11)

1,549

250

525

-

-

-

-

-

Interest paid in-kind on long-term debt (note 11)

778

0

0

-

-

-

-

-

Amortization of deferred financing fees

-

-

-

222

0

-

-

-

Restructuring costs settled by share issuance (note 18)

-

-

-

-

-

-342

-

-

Stock-based compensation expense, net (note 14)

2,065

260

2,205

1,141

645

546

1,931

3,277

Write-down of property and equipment

-

-

-

188

0

-

-

-

Write-down of inventory (note 7)

295

159

2,028

1,547

0

-

-

-

Deferred leasehold inducement

-

-

-

-

-

561

123

193

Loss on extinguishment of long-term debt (note 11)

0

-1,402

0

-

20,834

11,218

0

0

Unrealized foreign exchange loss (gain)

1,738

-210

43

520

186

133

61

180

Impairment of property and equipment

-

-

-

-

-

717

0

0

Changes in operating assets and liabilities:
Restricted cash

-687

296

31

175

2,059

-156

-

-

Loss on write-down of intangible assets

-

-

-

-

-

-

95

25

Accounts receivable

-448

-506

-3,067

3,495

-448

-270

506

-711

Inventories

1,533

375

1,094

286

2,816

0

-

-

Prepaid expenses and other assets

-510

37

-212

393

18

-14

-372

505

Deferred consideration

-

-

-

-558

0

-

-

-

Deferred revenue

-197

-272

1,885

0

-

-

-

-

Accounts payable and accrued liabilities

-675

-1,028

-2,738

-121

2,630

2,011

-2,492

-1,914

Other long-term liabilities

-31

-31

0

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

0

-35,197

Net cash used in operating activities

-24,136

-15,887

-16,269

-18,527

-16,768

-24,942

-27,609

2,677

Investing activities:
Restricted cash paid on acquisition (note 4)

-

-

-

-

1,266

0

-

-

Restricted cash acquired on acquisition (note 4)

-

-

-

-

1,143

0

-

-

Purchase of property and equipment

5

9

132

522

39

141

676

274

Purchase of intangible assets (note 9)

5,229

13,628

39

78

147

292

343

310

Net cash used in investing activities

-5,234

-13,637

-171

-600

-309

-433

-1,019

-584

Financing activities:
Issuance of common stock (note 13(b))

8,487

35,341

28,334

13,821

0

-

-

-

Share issue costs

1,072

2,746

1,650

1,415

0

-

-

-

Issuance of common stock upon exercise of stock options (note 13(b))

384

0

293

148

8

0

358

2,359

Income tax withholdings on vesting of restricted share units

65

95

38

-

-

-

-

-

Proceeds from issuance of long-term debt (note 11)

20,000

20,000

0

12,000

0

25,000

0

25,000

Financing fees on issuance of long-term debt (note 11)

518

713

106

1,043

0

-

-

-

Proceeds from sale of property and equipment

-

-

-

-

149

70

0

0

Repayment of long-term debt (note 11)

0

10,000

2,000

0

13,000

7,000

0

0

Payment of fees on extinguishment of long-term debt (note 11)

0

1,146

0

-

-

-

-

-

Payment of deferred consideration (note 12)

2,815

2,174

3,049

2,540

0

-

-

-

Net cash provided by financing activities

24,401

38,467

21,784

20,971

-12,843

18,070

358

27,359

Increase (decrease) in cash and cash equivalents during the year

-4,969

8,943

5,344

1,724

-30,019

-7,221

-28,244

29,618

Effect of foreign exchange rate changes on cash and cash equivalents

292

154

-391

-120

-99

84

26

166

Supplemental cash flow information:
Interest paid

3,477

2,329

1,826

-

-

-

-

-

Interest paid

-

-

-

1,104

0

2,238

2,241

1,991

Interest received

95

17

20

46

10

22

-

-

Cash received (paid) for income taxes

334

109

-693

-

-

-

-

-

Net income taxes paid

-

-

-

332

73

0

-

-

Non-cash purchase of Correvio (note 4)

-

-

-

-

20,314

0

-

-

Interest received

-

-

-

-

-

-

22

16